Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: Dexanabinol and PRS-211,220

The aim of this article was to investigate the role of intestinal lymphatic transport in the oral bioavailability of two structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. For this purpose, the long chain triglyceride (LCT) solubility and affinity to chylomicrons ex vivo of both cannabinoids were evaluated. Their oral bioavailability was assessed in rats following administration in a lipid-free and a LCT-based formulation. The intestinal lymphatic transport of these two molecules was also directly measured in a freely moving rat model. LCT solubility of dexanabinol and PRS-211,220 was 7.9 ± 0.2 and 95.8 ± 5.3 mg/g, respectively. The uptake by chylomicrons was moderate (31.6 ± 5.2%) and high (66.1 ± 2.4%), respectively. The bioavailability of dexanabinol (37%) was not affected by LCT solution, whereas administration of PRS-211,220 in LCT improved the absolute oral bioavailability three-fold (from 13 to 35%) in comparison to the lipid-free formulation. The intestinal lymphatic transport of dexanabinol and PRS-211,220 was 7.5 ± 0.8 and 60.7 ± 6.8% of the absorbed dose, respectively. In conclusion, despite structural similarity and similar lipophilicity, dexanabinol and PRS-211,220 exhibited a very diverse pattern of oral absorption, and the lymphatic system played quite a different role in the oral bioavailability of these molecules. The low lymphatic transport of dexanabinol is likely driven by relatively lower affinity to chylomicrons and lower LCT solubility.     

Development of HPLC plasma assays for CAM 4515 and CAM 4750, two new nonpeptide tachykinin antagonists, and application to bioavailability studies

CAM 4515 and CAM 4750 are new nonpeptide tachykinin NK₁ receptor antagonists with different lipophilicities. Two separate, simple, and sensitive HPLC methods for the quantitation of these two compounds in plasma and the evaluation of their oral bioavailability in rats were developed and validated. Extraction of CAM 4515 from plasma involved protein precipitation with acetonitrile, while that for CAM 4750 involved a one-step liquid-liquid extraction with methylene chloride. The analytes in extracts were chromatographed on a C18 column using two different separation buffers, 47% 0.02 M sodium citrate (pH 3.5)-53% acetonitrile for CAM 4515 and 59% 0.02 M potassium phosphate dibasic (pH 7.0)-41% acetonitrile for CAM 4750, and both compounds were detected by fluorescence (excitation 278 nm; emission 342 nm). Stability profiles of both drugs at −20°C or room temperature in plasma and in reconstituted buffers were good. The limit of quantitation for both drugs was 5 ng ml⁻¹ with good linearity from 5 to 1000 ng ml⁻¹ using 100–200 μl of plasma. Excellent precision (relative standard deviation < 8.3%) and accuracy (relative error ± 9.2%) were observed for both CAM 4515 and CAM 4750. Oral bioavailability studies were conducted for each compound in rats receiving a p.o. dose of 20 mg kg⁻¹ and an i.v. dose of 5 mg kg⁻¹. The absolute oral bioavailability of CAM 4750 (80%) was estimated to be 40-fold greater than that of CAM 4515 (2%). The experimental results suggest that incorporation of a pyridine group into the structural backbone may greatly improve bioavailability.     

氟罗沙星片剂,胶囊剂的人体药物动力学和相对生物利用度研究

9名男性健康自愿受试者采用三交叉单剂口服国产氛罗沙星片剂、胶囊和进口氟罗沙星片剂各400mg的药代动力学参数比较。血、尿药浓度用HPLC检测．结果表明：体内过程符合一室模型，主要药代动力学参数分别为：AUC：82.30±14．30、81．13±8．45与83．92±14.27h·mg／L；Cmax：4．71±0．83、4．67±0．51与4．86±0．89mg／L；Tmax：1．88±0．44、1．90±0．39与1．92±0．23h；T1／2ke：11．02±0．96、10．93±0．68与10．86±0．82h；V／F（c）：79．08±13．31、78.42±8．70与76．39±12．93L；Cl／F：5．00±0．98、4．98±0．52与4．88±0．73L／h。服药48h的尿中原型药排出率分别为给药量的57．4％，55．9％和60．7％。国产氧罗沙星片剂和胶囊口服后药物动力学参数与进口片剂相仿．其相对生物利用及分别为98.07％与96．68％。     

The bioavailability and nonlinear pharmacokinetics of MK-679 in humans

MK-679 (R(?)-3-((3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)(3-(dimethylamino)-3-oxopropyl)thio)methyl)thio(propanoic acid) is a potent and specific LTD₄-receptor antagonist. The disposition of MK-679 was investigated in a three-way crossover study in 12 healthy males receiving single intravenous doses of 75, 250, and 500 mg of MK-679. A greater than proportional increase in the area under the plasma concentration—time curve of MK-679 was observed with increase in dose. The plasma concentration data for each subject fitted well to the differential equations for a two-compartment model with linear tissue distribution and Michaelis-Menten elimination from the central compartment, indicating that the elimination of MK-679 in humans is saturable. In a previous study, the disposition of MK-679 in humans was also dose-dependent when given together with its S(+)-isomer, L-668,018. Thus, the disposition of MK-679 in humans is dose-dependent regardless of the presence of its stereoisomer. Also, the bioavailability of MK-679 was determined in six healthy males receiving simultaneously an oral dose of 250 mg of MK-679 and intravenous infusion of 1 mg ¹⁴C-MK-679. Results of this study indicate that the oral bioavailability of MK-679 is nearly quantitative.     

Bioavailability of intramuscularly administered tenoxicam

Bioavailability of intramuscularly administered tenoxicam relative to single oral and relative to intravenous doses was determined in two separate randomized crossover studies. Twelve healthy volunteers (12 males, age 20–30 years) received a rapid intravenous injection and a single intramuscular dose and 12 other subjects (11 males, 1 female, age 21–25 years) a single oral and a single intramuscular dose of 20 mg of tenoxicam on two different occasions. The wash-out period between the two consecutive treatments was 4 weeks. Plasma concentrations after dosing were determined by a specific HPLC method. Differences in tenoxicam concentration-time profiles after the different routes of administration were limited to the first 2 h after dosing. Later, plasma concentrations were almost superimposable within and across the two studies. The extent of absorption of intramuscularly administered tenoxicam was complete (mean ± CV per cent: F_abs 0.99 ± 20 per cent) with no difference between the two extravascular administrations (F_rel 0.95 ± 10 per cent, intramuscular vs oral). After intramuscular administration tenoxicam was more rapidly absorbed compared to the oral dose (T_max 0.71 h ± 80 per cent vs 1.4 h ± 62 per cent; p>0.05). Peak concentrations after oral and intramuscular administration (C_max 2.5 mg 1^?1 ± 19 per cent vs 2.7 mg l^?1 14 per cent; p <0.05) were very similar.     

头孢他美酯分散片在人体内的相对生物利用度及生物等效性

目的建立HPLC法测定人血浆中头孢他美的浓度,并研究头孢他美酯分散片在人体内的相对生物利用度及生物等效性。方法18名受试者随机均分成两组,先后单剂量po受试制剂或参比制剂后,采用HPLC法测定血药浓度,计算药动学参数并进行生物等效性判定。结果单次服用0.5 g受试制剂或参比制剂后的药动学参数AUC0→14、AUC0→∞、Tm ax、Cm ax、t1/2分别为22.07±3.98μg.h.m l-1和21.31±4.37μg.h.m l-1,22.62±4.06μg.h.m l-1和21.99±4.54μg.h.m l-1,2.42±0.55 h和2.61±0.50 h,4.16±0.74μg.m l-1和3.95±0.87μg.m l-1,2.24±0.26 h和2.48±0.33 h。实验制剂对参比制剂的相对生物利用度为105.0%±14.6%。两种制剂的药动学参数无明显差异。结论受试制剂与参比制剂具有生物等效性。     

非洛地平缓释片在兔体内药物动力学和生物利用度比较

目的 比较几种国产非洛地平缓释片在兔体内的药物动力学和生物利用度.方法 用高效液相色谱法测定兔口服药物后血浆中的药物浓度,以普通非洛地平片作为参照,计算其药物动力学和生物利用度.结果 在1.0-80μg·L-1范围内,非洛地平血浆药物浓度与色谱峰高呈良好的线性关系.单剂量兔血浆中非洛地平缓释片动力学参数不同产品存在差异,相对于普通制剂的生物利用度分别为179%、162%、122%.结论 不同产品非洛地平缓释片药物动力学和生物利用度存在差别.     

Effect of dietary fat content on the bioavailability of a sustained release quinidine gluconate tablet

Quinidine gluconate 324 mg sustained release tablets (Quinaglute) was administered as a single dose to 15 healthy male subjects following an overnight fast, immediately following a high fat (HF) breakfast or immediately following a low fat (LF) breakfast. Serum samples were obtained over a 48 h period and analyzed for quinidine content using a high performance liquid chromatographic assay. Under the conditions of the study, both the rate and extent of quinidine bioavailability was significantly affected by food. The extent of bioavailability was statistically significantly greater (p less than 0.05) following both the HF and LF meals as compared to that in the fasted state. Rate of bioavailability was significantly enhanced following the LF meal as compared to that of the other two treatment groups. Although peak concentrations were greater and time to peak concentrations somewhat later following the HF meal versus those under fasting conditions, these differences were not statistically significant. In addition, the characteristics of the serum concentration-time profile (as defined by the number, magnitude, and time of occurrence of the multiple absorption maxima) was unique for each of the three treatment groups. Possible mechanisms underlying these results are explored.     

高效液相色谱法测定利福定尿药浓度及生物利用度

本文用反相高效液相色谱法测定了利福定在人体尿液中的浓度。色谱条件为:Shimpack CLC-TMS 5μm柱(150×4.6mm);0.01M磷酸二氢钾缓冲液—乙腈(50:50)为流动相;检测波长316nm.尿中利福定在0.2～20μg/ml的范围内呈线性关系。有机溶媒提取率为93%.用本法测定了利福定固体分散物相对于原药的生物利用度为147.7%.     

Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man

Eight normal male volunteers received 80 mg doses of propranolol by the oral and rectal routes and 2.2 mg by intravenous administration in a crossover fashion. Plasma concentrations of propranolol were measured by a gas chromatographic method using an electron capture detector. Individual subject concentration-time data were analysed and results indicated that the data fit a two compartment model with first order absorption. An approximately two-fold higher plasma propranolol concentration was observed after rectal administration as compared with oral dosing. Statistical analysis of the difference in the total AUCs indicates a significantly higher bioavailability of propranolol administered by the rectal route. The reduced bioavailability after oral administration indicates a substantial first pass effect but that it is possible to bypass the liver, at least partially, by giving the drug rectally to man.